Harnessing the Power of Protein Degradation for the Extracellular Proteome


Our pioneering LYTAC (Lysosomal Targeting Chimera) Platform enables targeted degradation of extracellular proteins.

We are utilizing our LYTAC platform to advance a pipeline of first-in-class LYTAC extracellular protein degraders aimed at depleting difficult-to-drug targets, including many that, to date, have been intractable. Our initial pipeline focus is on programs for autoimmune and inflammatory diseases.

Learn More


We are building a stellar team, driven to pioneer breakthrough science and motivated to make a
difference for patients.

Meet Our Team

come join us, we’re hiring!